The Stochastic Oscillator for AEMD moved into oversold territory on November 14, 2024. Be on the watch for the price uptrend or consolidation in the future. At that time, consider buying the stock or exploring call options.
The Momentum Indicator moved above the 0 level on November 07, 2024. You may want to consider a long position or call options on AEMD as a result. In of 69 past instances where the momentum indicator moved above 0, the stock continued to climb. The odds of a continued upward trend are .
The Moving Average Convergence Divergence (MACD) for AEMD just turned positive on October 30, 2024. Looking at past instances where AEMD's MACD turned positive, the stock continued to rise in of 40 cases over the following month. The odds of a continued upward trend are .
The 10-day moving average for AEMD crossed bullishly above the 50-day moving average on November 11, 2024. This indicates that the trend has shifted higher and could be considered a buy signal. In of 15 past instances when the 10-day crossed above the 50-day, the stock continued to move higher over the following month. The odds of a continued upward trend are .
Following a 3-day Advance, the price is estimated to grow further. Considering data from situations where AEMD advanced for three days, in of 200 cases, the price rose further within the following month. The odds of a continued upward trend are .
AEMD moved below its 50-day moving average on November 14, 2024 date and that indicates a change from an upward trend to a downward trend.
AEMD broke above its upper Bollinger Band on November 11, 2024. This could be a sign that the stock is set to drop as the stock moves back below the upper band and toward the middle band. You may want to consider selling the stock or exploring put options.
The Tickeron Valuation Rating of (best 1 - 100 worst) indicates that the company is slightly undervalued in the industry. This rating compares market capitalization estimated by our proprietary formula with the current market capitalization. This rating is based on the following metrics, as compared to industry averages: P/B Ratio (0.596) is normal, around the industry mean (22.930). P/E Ratio (0.000) is within average values for comparable stocks, (83.945). Projected Growth (PEG Ratio) (0.000) is also within normal values, averaging (5.605). Dividend Yield (0.000) settles around the average of (0.018) among similar stocks. P/S Ratio (7.326) is also within normal values, averaging (43.286).
The Tickeron Price Growth Rating for this company is (best 1 - 100 worst), indicating steady price growth. AEMD’s price grows at a higher rate over the last 12 months as compared to S&P 500 index constituents.
The Tickeron SMR rating for this company is (best 1 - 100 worst), indicating weak sales and an unprofitable business model. SMR (Sales, Margin, Return on Equity) rating is based on comparative analysis of weighted Sales, Income Margin and Return on Equity values compared against S&P 500 index constituents. The weighted SMR value is a proprietary formula developed by Tickeron and represents an overall profitability measure for a stock.
The Tickeron PE Growth Rating for this company is (best 1 - 100 worst), pointing to worse than average earnings growth. The PE Growth rating is based on a comparative analysis of stock PE ratio increase over the last 12 months compared against S&P 500 index constituents.
The Tickeron Profit vs. Risk Rating rating for this company is (best 1 - 100 worst), indicating that the returns do not compensate for the risks. AEMD’s unstable profits reported over time resulted in significant Drawdowns within these last five years. A stable profit reduces stock drawdown and volatility. The average Profit vs. Risk Rating rating for the industry is 87, placing this stock worse than average.
a provider of diagnostic and therapeutic device solutions for infectious disease, cancer and for other life threatening conditions
Industry MedicalSpecialties